Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Preferred Stock Liabilities (2021)

Amylyx Pharmaceuticals (AMLX) has 1 years of Preferred Stock Liabilities data on record, last reported at $239.4 million in Q4 2021.

  • For Q4 2021, Preferred Stock Liabilities changed N/A year-over-year to $239.4 million; the TTM value through Dec 2021 reached $239.4 million, changed N/A, while the annual FY2021 figure was $239.4 million, N/A changed from the prior year.
  • Preferred Stock Liabilities reached $239.4 million in Q4 2021 per AMLX's latest filing, up from $64.4 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $239.4 million in Q4 2021 and bottomed at $64.4 million in Q1 2021.